Rockefeller Capital Management L.P. cut its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 28.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 210,860 shares of the company’s stock after selling 84,560 shares during the period. Rockefeller Capital Management L.P.’s holdings in Zoetis were worth $26,531,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. RFG Advisory LLC boosted its position in Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares during the last quarter. YANKCOM Partnership increased its position in shares of Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after purchasing an additional 81 shares during the last quarter. Beese Fulmer Investment Management Inc. raised its stake in shares of Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares during the period. Quest 10 Wealth Builders Inc. raised its stake in shares of Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares during the period. Finally, Financial Engines Advisors L.L.C. boosted its holdings in shares of Zoetis by 4.4% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after buying an additional 87 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.
Zoetis Trading Down 3.6%
Shares of ZTS opened at $75.89 on Tuesday. The business has a 50-day moving average of $92.13 and a 200 day moving average of $112.10. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $161.77. The firm has a market cap of $31.82 billion, a P/E ratio of 12.59, a price-to-earnings-growth ratio of 1.23 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.
Zoetis Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s payout ratio is 35.16%.
Insider Activity at Zoetis
In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on ZTS. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. UBS Group reduced their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Friday, May 22nd. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $133.92.
View Our Latest Analysis on Zoetis
About Zoetis
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Read More
- Five stocks we like better than Zoetis
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
